<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05084625</url>
  </required_header>
  <id_info>
    <org_study_id>2021-02902</org_study_id>
    <nct_id>NCT05084625</nct_id>
  </id_info>
  <brief_title>PACED-digitized Support During Adjuvant Endocrine Therapy</brief_title>
  <official_title>PACED-Patient-centred Digital Support During Adjuvant Endocrine Breast Cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Stockholm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ScientificMed Tech AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Sverige AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bröstcancerförbundet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stockholm South General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Capio St Gorans hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Stockholm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The research team want to investigate whether digital support, an app under preventive&#xD;
      hormonal breast cancer treatment can lead to less late side effects, better quality of life&#xD;
      and increased adherence to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with hormon receptor positive breast cancer and adjuvant endocrine treatment will be&#xD;
      invited to participate in the study after adjuvant radiotherapy is completed. Participants&#xD;
      will be randomised to 12 months of access to a digital support-an app-in addition to standard&#xD;
      follow-up or standard follow-up. Research team want to investigate whether digital support&#xD;
      under hormonal breast cancer treatment can lead to less late side effects, better quality of&#xD;
      life and increased adherence to treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference between the two groups with regard to change in quality of life from baseline to 12 months measured by Questionnaires European Organisation for Research and Treatment for Cancer Quality of life C30 (EORTC QLQ C30).</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
    <description>EORTC QLQ C30. All of the scales and single-item measures range in score from 0 to100. A high scale score represents a higher response level. For a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. A 'little' change for better or worse on a particular scale (function or symptom) defined as changes about 5 to 10. &quot;Moderate&quot; change have changed about 10 to 20, and 'very much' change corresponded to a change greater than 20. Our population sample is based on that a change should be of effect size (Cohen's d) difference of 0.54 (which correspond to a moderate change) at the end of access to digital support in the primary outcome of symptom burden and quality of life, 90% power at P &lt; .01</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference between the two groups with regard to change in quality of life from baseline to 12 months by Questionnaires European Organisation for Research and Treatment for Cancer Quality of life Breast cancerrelated 23 (EORTC QLQ BR23)</measure>
    <time_frame>Change from baseline to 12 months</time_frame>
    <description>EORTC QLQ BR23. All of the scales and single-item measures range in score from 0 to100. A high scale score represents a higher response level. For a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. A 'little' change for better or worse on a particular scale (function or symptom) defined as changes about 5 to 10. &quot;Moderate&quot; change have changed about 10 to 20, and 'very much' change corresponded to a change greater than 20. BR23 recommended with C30. Our population sample is based on that a change should be of effect size (Cohen's d) difference of 0.54 (which correspond to a moderate change) at the end of access to digital support in the primary outcome of symptom burden and quality of life, 90% power at P &lt; .01</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Treatment Adherence</condition>
  <condition>Quality of Life</condition>
  <condition>Treatment Side Effects</condition>
  <arm_group>
    <arm_group_label>Arm A- access to digitized support, an app</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in Arm A will have access to digitized support-an app for 12 months from baseline in addition to standard follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B-standard follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in Arm B-will continue with standard follow-up from baseline and onwards</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Digitized support</intervention_name>
    <description>Access to information about the disease, treatment, side effects and self-care</description>
    <arm_group_label>Arm A- access to digitized support, an app</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hormone receptor positive breast cancer&#xD;
&#xD;
          -  On adjuvant endocrine treatment 0-16 weeks ago&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cognitively impaired&#xD;
&#xD;
          -  No access to a mobile phone or internet&#xD;
&#xD;
          -  Not understanding Swedish&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jenny Bergqvist</last_name>
    <role>Principal Investigator</role>
    <affiliation>St Gorans Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jenny Bergqvist</last_name>
    <phone>+46700891524</phone>
    <email>jenny.bergqvist@ki.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hallin, PI</last_name>
    <phone>+46700891524</phone>
    <email>charlotta.hallin@capiostgoran.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Yvonne Wengström</last_name>
      <email>yvonne.wengstrom@ki.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>Anna Larsson-Wrake</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 6, 2021</study_first_submitted>
  <study_first_submitted_qc>October 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Digital support</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

